Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Company Deals

Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration

Fineline Cube May 13, 2026
Policy / Regulatory

China’s NHSA Unveils Five-Year Medical Insurance Fund Supervision Plan (2026–2030) – AI-Powered Oversight to Combat Fraud Across Healthcare Ecosystem

Fineline Cube May 14, 2026
Company Drug

BeOne Medicines’ BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma – 52% Response Rate in Phase I/II Study

Fineline Cube May 14, 2026
Company Drug

Zhongsheng Pharma’s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication – Phase III Data Shows Favorable Efficacy vs. Tamiflu

Fineline Cube May 14, 2026
Company Drug

CSPC’s JMT103 Accepted for Review in China, Targets RANKL-Related Deficiencies

Fineline Cube Jun 22, 2022

The Center for Drug Evaluation (CDE) website indicates that a market filing by China-based CSPC...

Company Medical Device

Grand Pharma Launches SIR-Spheres for Liver Cancer Treatment in China

Fineline Cube Jun 22, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the official launch of its SIR-Spheres...

Policy / Regulatory R&D

Beijing Introduces White List System for Biomedical R&D Item Imports

Fineline Cube Jun 21, 2022

Beijing has announced the introduction of a ‘white list’ system to facilitate the import of...

Company Drug

Ocumension Therapeutics’ OT-401 Approved for Chronic Non-Infectious Uveitis in China

Fineline Cube Jun 21, 2022

China-based Ocumension Therapeutics (HKG: 1477) has received approval from the National Medical Products Administration (NMPA)...

Company

AstraZeneca Expands in China with Qingdao Partnership and Manufacturing Base

Fineline Cube Jun 21, 2022

UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is significantly expanding its presence in China through a...

Company Drug

CStone Pharmaceuticals’ Ayvakit Included in Taiwan’s National Health Insurance

Fineline Cube Jun 21, 2022

China-based CStone Pharmaceuticals (HKG: 2616) announced that its Ayvakit (avapritinib), a tyrosine kinase inhibitor for...

Company Deals

Eureka Biotechnology Secures RMB 100 Million for Cell and Gene Therapy Solutions

Fineline Cube Jun 21, 2022

Shenzhen-based Eureka Biotechnology, a company specializing in comprehensive solutions for the cell and gene therapy...

Company Deals

Therorna Secures Over RMB 280 Million in Series A Round to Accelerate circRNA Tech Development

Fineline Cube Jun 21, 2022

China-based Therorna Inc., a biotech company specializing in cutting-edge circular RNA (circRNA) technology for next-generation...

Company Medical Device

Qingdao HuaRen Pharmaceutical Gains CE Marks for Monkeypox and COVID-19 Detection Kits

Fineline Cube Jun 21, 2022

China-based Qingdao HuaRen Pharmaceutical Co., Ltd (SHE: 300110) has announced receiving CE marks in the...

Company Drug

SSY Group’s Blonanserin and Paracetamol Approved by China’s NMPA

Fineline Cube Jun 21, 2022

China-based SSY Group Limited (HKG: 2005) has announced receiving market approvals from the National Medical...

Company Deals

Shanghai ShineYo Medical Device Secures RMB 100 Million in Series A Round

Fineline Cube Jun 21, 2022

Shanghai ShineYo Medical Device Co., Ltd, a company specializing in electrophysiology and peripheral intervention, has...

Company Deals R&D

Boehringer Ingelheim Venture Fund and Hong Kong Science Park Launch Co-Incubation Plan

Fineline Cube Jun 20, 2022

Germany-based pharmaceutical giant Boehringer Ingelheim’s venture fund (BIVF) and China-based Hong Kong Science & Technology...

Company Drug

Innovent Biologics’ Tyvyt Approved for First-Line Esophageal Squamous Cell Carcinoma

Fineline Cube Jun 20, 2022

The National Medical Products Administration (NMPA) website indicates that China-based Innovent Biologics, Inc. (HKG: 1801)...

Policy / Regulatory

China’s Seventh National Volume-based Procurement Round Kicks Off with Revised Rules

Fineline Cube Jun 20, 2022

China’s health authorities have resumed the seventh national volume-based procurement (VBP) round after a pandemic-related...

Company Deals

Shenzhen AXBio Closes USD 100 Million Series B Round for Sequencing Tech Expansion

Fineline Cube Jun 20, 2022

Shenzhen-based fourth-generation sequencing company Anxuyuan Biotechnology (shenzhen) Company Limited (AXBio) has reportedly secured close to...

Company Medical Device

Boston Scientific Launches Expect Airway Ultrasound Needle in China for Lung Cancer Diagnosis

Fineline Cube Jun 20, 2022

US-based Boston Scientific Corporation (NYSE: BSX) has announced the official market launch of its Expect...

Company Deals

Iomics Biosciences Secures RMB 100 Million for Proteomics and Spatialomics Expansion

Fineline Cube Jun 20, 2022

Beijing-based Iomics Biosciences Co., Ltd, a developer of gene sequencing and diagnostic equipment, has reportedly...

Company Drug

InnoCare and Keymed Biosciences’ CCR8-Targeted mAb CM369 Accepted by NMPA

Fineline Cube Jun 20, 2022

China-based InnoCare (HKG: 9969) and Keymed Biosciences Inc. (HKG: 2162) announced that an Investigational New...

Policy / Regulatory

CDE Releases 58th and 59th Batches of Chemical Generic Reference Preparations

Fineline Cube Jun 20, 2022

The Center for Drug Evaluation (CDE) has released the 58th and 59th batches of chemical...

Company Deals

Shenzhen’s LWPOCT Secures RMB 100 Million in Series A Round for CDMO Expansion

Fineline Cube Jun 20, 2022

Shenzhen-based medical devices and reagents manufacturer Shenzhen Living Water POCT Co., LTd (LWPOCT) has reportedly...

Posts pagination

1 … 659 660 661 … 665

Recent updates

  • BeOne Medicines’ BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma – 52% Response Rate in Phase I/II Study
  • China’s NHSA Unveils Five-Year Medical Insurance Fund Supervision Plan (2026–2030) – AI-Powered Oversight to Combat Fraud Across Healthcare Ecosystem
  • Zhongsheng Pharma’s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication – Phase III Data Shows Favorable Efficacy vs. Tamiflu
  • Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer – Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential
  • Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BeOne Medicines’ BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma – 52% Response Rate in Phase I/II Study

Policy / Regulatory

China’s NHSA Unveils Five-Year Medical Insurance Fund Supervision Plan (2026–2030) – AI-Powered Oversight to Combat Fraud Across Healthcare Ecosystem

Company Drug

Zhongsheng Pharma’s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication – Phase III Data Shows Favorable Efficacy vs. Tamiflu

Company Drug

Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer – Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.